REGENXBIO Inc. RGNX
7.63 USD +0.47 (+6.56%)
At closeNov 3, 2026, 4:01 PM EST
7.63 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
7.27 Day range 7.65
5.46 52-week range 16.19
- YTD
- -47.01%
- 1 year
- -36.36%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.64 +393.3% upside
Now 7.63
- Target (low)
- 22.00
- Target (mean)
- 37.64
- Target (high)
- 52.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy5
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 13
- 2 months ago 13
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.11 | -1.36 – -0.462 | -1.43 | +22.7% | 23.52M | +5.9% | 8 |
| Next quarter | -1.17 | -1.35 – -1.04 | -1.34 | +12.4% | 19.93M | +27.6% | 3 |
| Current year | -4.78 | -5.47 – -4.03 | -6.02 | +20.6% | 87.07M | -3.5% | 9 |
| Next year | -0.8061 | -2.91 – 1.85 | -4.78 | +83.1% | 300.30M | +244.9% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Nov 21, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 22, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 5, 2024 | Barclays | Maintained | Overweight | Overweight |
| Aug 5, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 7, 2024 | Goldman Sachs | Initiated | — | Buy |
| May 15, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 12, 2024 | Stifel | Maintained | Buy | Buy |
| Mar 11, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 8, 2024 | RBC Capital | Upgrade | Sector Perform | Outperform |
| Mar 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Mar 7, 2024 | Barclays | Maintained | Overweight | Overweight |
| Mar 6, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Mar 6, 2024 | Baird | Maintained | Outperform | Outperform |
| Feb 28, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Feb 12, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Nov 1, 2023 | Stifel | Initiated | — | Buy |
| Oct 5, 2023 | Wedbush | Reiterated | Neutral | Neutral |
| Oct 4, 2023 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Aug 29, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 3, 2023 | Chardan Capital | Reiterated | — | Buy |
| Jul 12, 2023 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Jun 20, 2023 | Baird | Initiated | — | Outperform |
| Jun 2, 2023 | Baird | Initiated | — | Outperform |
| May 9, 2023 | Morgan Stanley | Maintained | — | Overweight |
| May 5, 2023 | Chardan Capital | Maintained | — | Buy |